← Back to Treatments
🏅 FDA Orphan Designation

Gliadel

polifeprosan 20 with carmustine

Manufacturer: Guilford Pharmaceuticals, Inc.

Indicated for:
Rare ovarian cancerOrphanHigh-grade astrocytomaRetinoblastoma

FDA-Approved Indications (3)

Rare ovarian cancerOrphan Designation

As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated

newly-diagnosed high-grade glioma as an adjunct to surgery and radiation

Population: all ages

recurrent glioblastoma as an adjunct to surgery

Population: all ages

Indications & Usage

1 INDICATIONS AND USAGE GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation ( 1 ) and recurrent glioblastoma as an adjunct to surgery ( 1 )

💙 Support Programs

View all →
Gliadel
Guilford Pharmaceuticals, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.